{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T16:11:14Z","timestamp":1759853474206,"version":"build-2065373602"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,7]]},"DOI":"10.7759\/cureus.94034","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T15:37:28Z","timestamp":1759851448000},"source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Challenges in Managing Triple-Negative Breast Cancer in a Patient With Central Core Disease"],"prefix":"10.7759","author":[{"given":"Fatima","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eeman","family":"Noor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asfandyar","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usman","family":"Sehbai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aasim","family":"Sehbai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Breast Cancer Facts & Stats. (2025). Accessed. May 1, 2025: https:\/\/www.nationalbreastcancer.org\/breast-cancer-facts\/."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.25122\/jml-2021-0108","article-title":"Triple-negative breast cancer: current treatment strategies and factors of negative prognosis","volume":"15","author":"Baranova A","year":"2022","unstructured":"Baranova A, Krasnoselskyi M, Starikov V, et al.. Triple-negative breast cancer: current treatment strategies and factors of negative prognosis. J Med Life. 2022, 15:153-61. 10.25122\/jml-2021-0108","journal-title":"J Med Life"},{"key":"ref3","unstructured":"Triple negative breast cancer. (2025). Accessed. May 1, 2025: https:\/\/www.nationalbreastcancer.org\/triple-negative-breast-cancer\/."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple negative breast cancer treatment options and limitations: future outlook","volume":"15","author":"Obidiro O","year":"2023","unstructured":"Obidiro O, Battogtokh G, Akala EO. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics. 2023, 15:1796. 10.3390\/pharmaceutics15071796","journal-title":"Pharmaceutics"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/genes13050760","article-title":"Central core disease: facial weakness differentiating biallelic from monoallelic forms","volume":"13","author":"Cotta A","year":"2022","unstructured":"Cotta A, Souza LS, Carvalho E, et al.. Central core disease: facial weakness differentiating biallelic from monoallelic forms. Genes (Basel). 2022, 13:760. 10.3390\/genes13050760","journal-title":"Genes (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143615","article-title":"Chemotherapy-induced myopathy: the dark side of the cachexia sphere","volume":"13","author":"Campelj DG","year":"2021","unstructured":"Campelj DG, Goodman CA, Rybalka E. Chemotherapy-induced myopathy: the dark side of the cachexia sphere. Cancers (Basel). 2021, 13:3615. 10.3390\/cancers13143615","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.06.1594","article-title":"Myopathy leading to rhabdomyolysis as a rare side effect of lenvatinib and pembroluzimab therapy","volume":"166","author":"Lord M","year":"2024","unstructured":"Lord M, Healey LA, Negin B. Myopathy leading to rhabdomyolysis as a rare side effect of lenvatinib and pembroluzimab therapy. Chest. 2024, 166:A2620-1. 10.1016\/j.chest.2024.06.1594","journal-title":"Chest"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11293-4","article-title":"Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis","volume":"23","author":"Cortes J","year":"2023","unstructured":"Cortes J, Haiderali A, Huang M, et al.. Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis. BMC Cancer. 2023, 23:792. 10.1186\/s12885-023-11293-4","journal-title":"BMC Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-2-25","article-title":"Central core disease","volume":"2","author":"Jungbluth H","year":"2007","unstructured":"Jungbluth H. Central core disease. Orphanet J Rare Dis. 2007, 2:25. 10.1186\/1750-1172-2-25","journal-title":"Orphanet J Rare Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.36185\/2532-1900-029","article-title":"Core myopathies - a short review","volume":"39","author":"Topaloglu H","year":"2020","unstructured":"Topaloglu H. Core myopathies - a short review. Acta Myol. 2020, 39:266-73. 10.36185\/2532-1900-029","journal-title":"Acta Myol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/23328940.2016.1153360","article-title":"Functional analysis of RYR1 variants linked to malignant hyperthermia","volume":"3","author":"Stephens J","year":"2016","unstructured":"Stephens J, Schiemann AH, Roesl C, et al.. Functional analysis of RYR1 variants linked to malignant hyperthermia. Temperature (Austin). 2016, 3:328-39. 10.1080\/23328940.2016.1153360","journal-title":"Temperature (Austin)"},{"key":"ref12","article-title":"Malignant hyperthermia","author":"Watt S","year":"2023","unstructured":"Watt S, McAllister RK. Malignant hyperthermia. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000542103","article-title":"Rhabdomyolysis occurred again after changing chemotherapy regimens in ovarian cancer: a case report","volume":"17","author":"Cao S","year":"2024","unstructured":"Cao S, Peng T. Rhabdomyolysis occurred again after changing chemotherapy regimens in ovarian cancer: a case report. Case Rep Oncol. 2024, 17:1322-6. 10.1159\/000542103","journal-title":"Case Rep Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-017-1272-9","article-title":"Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report","volume":"11","author":"Sokolova A","year":"2017","unstructured":"Sokolova A, Chan O, Ullah W, Hamdani AA, Anwer F. Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report. J Med Case Rep. 2017, 11:100. 10.1186\/s13256-017-1272-9","journal-title":"J Med Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2217\/lmt-2018-0017","article-title":"Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report","volume":"8","author":"Claus J","year":"2019","unstructured":"Claus J, Van Den Bergh A, Verbeek S, Wauters E, Nackaerts K. Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report. Lung Cancer Manag. 2019, 8:LMT10. 10.2217\/lmt-2018-0017","journal-title":"Lung Cancer Manag"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2020.09.029","article-title":"Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group","volume":"126","author":"R\u00fcffert H","year":"2021","unstructured":"R\u00fcffert H, Bastian B, Bendixen D, et al.. Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group. Br J Anaesth. 2021, 126:120-30. 10.1016\/j.bja.2020.09.029","journal-title":"Br J Anaesth"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/370259-therapeutic-challenges-in-managing-triple-negative-breast-cancer-in-a-patient-with-central-core-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T15:37:30Z","timestamp":1759851450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/370259-therapeutic-challenges-in-managing-triple-negative-breast-cancer-in-a-patient-with-central-core-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.94034","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,10,7]]}}}